An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer.
about
Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53The significance of immunohistochemistry in the diagnosis and therapy of neoplasms.c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes.c-erbB-2 oncoprotein expression in primary and advanced breast cancerc-erbB-2 positive breast tumours behave more aggressively in the first years after diagnosis.Pathological and biological features of mammographically detected invasive breast carcinomasSignificance of epidermal growth factor receptor and c-erbB-2 protein expression in transitional cell cancer of the upper urinary tract for tumour recurrence at the urinary bladder.C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators.Breast carcinomas occurring in young women (< 35 years) are different.c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival.Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancerIsolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6.HER2 (c-erbB-2) oncoprotein expression in colorectal adenocarcinoma: an immunohistological study using three different antibodies.Frequency of the basal-like phenotype in African breast cancer.E-cadherin relates to EGFR expression and lymph node metastasis in primary breast carcinomaBiological indices in the assessment of breast cancer.Two-dimensional gel database of human breast carcinoma cell expressed proteins: an update.c-erbB-2 oncogene as a prognostic marker in breast cancer.Prognostic value of c-erbB2 expression in breast cancer.Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma.Significance of immunohistochemical c-ErbB-2 product localisation pattern for prognosis in human breast cancer.Lack of association between HER2 codon 655 polymorphism and breast cancer susceptibility: meta-analysis of 22 studies involving 19,341 subjects.Proliferating cell nuclear antigen in breast lesions: correlation of c-erbB-2 oncoprotein and EGF receptor and its clinicopathological significance in breast cancer.The erbB/HER type 1 tyrosine kinase receptor family.HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy.
P2860
Q28363615-6B730D1D-8AFA-46E3-946D-19252694804FQ34602545-AC945E9E-ACAB-4DEE-BD43-5DEBF2E2FF66Q35983237-8649C318-4A2B-4E2F-897C-26E5100AF223Q35983286-77B7039F-53FB-46A0-B09E-F36CBD4364B1Q35993223-8E723E41-02AE-4D19-B7A8-60024465A812Q36079849-47C67DE0-9035-42FA-972B-5299F92E353DQ36079924-0D9FC5D6-9035-4216-BB90-E7680A901829Q36135449-B586E1EA-C072-4165-8846-1232F51605FAQ36141250-38EF4374-3242-4387-BF3D-03287E9511FDQ36421775-1ACB9A74-7B53-4154-9680-5BB0BAF72B09Q36431192-2ED2D0B1-04F6-4F37-906D-DB2FB6743127Q36618907-A9B1B5F2-8F86-4BAD-8F77-9954A7225BCDQ37110508-97E78F5A-BDE3-4DEE-8E74-9B4AF5490062Q38428225-6D44A24D-88A1-49C8-B76C-F2FBE7B10E42Q40027797-B3595286-DBCB-4806-9910-2A5FEBE989F2Q40848953-5A54A602-AE60-49EA-942B-EACEBF3D49AFQ41033581-196F8D43-CEE2-4115-A13C-CFBFC7D7870EQ42383432-34A4D483-3F75-442F-955F-959B28ED7635Q43427058-FFABD4A9-74C3-4CB7-B232-30B404240FB4Q43759908-0C851D76-883F-4B5B-9A57-AF3D2927E45DQ43787651-99E42015-665E-410B-9CF1-37068EFB1810Q44179953-84BDC2D0-7E9A-47AC-8263-1A880AC5D3BEQ44845527-3DC8275D-40CA-42AE-8030-82F649BC9526Q48376629-34DA83C3-6740-40DD-A1CC-868634DAF9C1Q50994494-F907FA5F-7D40-43B6-8D9E-35D14C8B069AQ54051061-EE8AE074-712D-4CE7-B933-4C6B0B480AFE
P2860
An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
An evaluation of immunoreactiv ...... rm prognosis in breast cancer.
@ast
An evaluation of immunoreactiv ...... rm prognosis in breast cancer.
@en
type
label
An evaluation of immunoreactiv ...... rm prognosis in breast cancer.
@ast
An evaluation of immunoreactiv ...... rm prognosis in breast cancer.
@en
prefLabel
An evaluation of immunoreactiv ...... rm prognosis in breast cancer.
@ast
An evaluation of immunoreactiv ...... rm prognosis in breast cancer.
@en
P2093
P2860
P356
P1476
An evaluation of immunoreactiv ...... rm prognosis in breast cancer.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1989.299
P407
P577
1989-09-01T00:00:00Z